Tsang ES, et al. - In this study, the authors analyzed 676 individuals with advanced pancreatic cancer (APC) to describe predicting factors and results of second-line chemotherapy in those with APC. Those getting second-line chemotherapy were younger, had lower ECOG, and higher CA19-9 at presentation. They observed no difference in rates of second-line chemotherapy between locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Only first-line FOLFIRINOX was related to second-line chemotherapy. They saw a longer median overall survival (OS) from second-line chemotherapy with second-line gemcitabine/nab-paclitaxel vs fluoropyrimidine or gemcitabine. A longer OS from second-line chemotherapy was correlated with gemcitabine/nab-paclitaxel, lower ECOG, and LAPC on multivariable analysis. They concluded first-line FOLFIRINOX as the most potent predictor of second-line chemotherapy.